BioAtla (BCAB) Competitors

BioAtla (NASDAQ:BCAB) and Amylyx Pharmaceuticals (NASDAQ:AMLX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their community ranking, dividends, analyst recommendations, risk, earnings, profitability, institutional ownership, media sentiment and valuation.

Do analysts recommend BCAB or AMLX?

BioAtla currently has a consensus price target of $6.00, indicating a potential upside of 284.62%. Amylyx Pharmaceuticals has a consensus price target of $15.14, indicating a potential upside of 218.13%. Given BioAtla's stronger consensus rating and higher probable upside, equities analysts clearly believe BioAtla is more favorable than Amylyx Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioAtla	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50
Amylyx Pharmaceuticals	0 Sell rating(s)	6 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

Does the media refer more to BCAB or AMLX?

In the previous week, BioAtla had 9 more articles in the media than Amylyx Pharmaceuticals. MarketBeat recorded 13 mentions for BioAtla and 4 mentions for Amylyx Pharmaceuticals. BioAtla's average media sentiment score of 0.53 beat Amylyx Pharmaceuticals' score of 0.50 indicating that BioAtla is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioAtla	2 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Amylyx Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Do institutionals and insiders believe in BCAB or AMLX?

77.2% of BioAtla shares are held by institutional investors. Comparatively, 95.8% of Amylyx Pharmaceuticals shares are held by institutional investors. 11.5% of BioAtla shares are held by insiders. Comparatively, 11.7% of Amylyx Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Does the MarketBeat Community prefer BCAB or AMLX?

Amylyx Pharmaceuticals received 5 more outperform votes than BioAtla when rated by MarketBeat users. However, 67.57% of users gave BioAtla an outperform vote while only 63.83% of users gave Amylyx Pharmaceuticals an outperform vote.

Company	Underperform	Outperform
BioAtla	Outperform Votes 25 67.57%	Underperform Votes 12 32.43%
Amylyx Pharmaceuticals	Outperform Votes 30 63.83%	Underperform Votes 17 36.17%

Which has stronger valuation & earnings, BCAB or AMLX?

Amylyx Pharmaceuticals has higher revenue and earnings than BioAtla. Amylyx Pharmaceuticals is trading at a lower price-to-earnings ratio than BioAtla, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioAtla	$11M	6.85	-$123.46M	-$1.70	-0.92
Amylyx Pharmaceuticals	$196.49M	1.66	$49.27M	-$3.82	-1.25

Which has more volatility & risk, BCAB or AMLX?

BioAtla has a beta of 1.03, indicating that its share price is 3% more volatile than the S&P 500. Comparatively, Amylyx Pharmaceuticals has a beta of -0.7, indicating that its share price is 170% less volatile than the S&P 500.

Is BCAB or AMLX more profitable?

BioAtla has a net margin of 0.00% compared to Amylyx Pharmaceuticals' net margin of -17.86%. Amylyx Pharmaceuticals' return on equity of -36.97% beat BioAtla's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioAtla	N/A	-187.30%	-96.33%
Amylyx Pharmaceuticals	-17.86%	-36.97%	-29.61%

Summary

BioAtla beats Amylyx Pharmaceuticals on 10 of the 18 factors compared between the two stocks.